Medical Therapy in Bph - Clinical Center

Clarke, Harry S.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Type: Research Project--Cooperative Agreements (U01)
• Project #: 3U01DK049961-02S1
• Application #: 2438230
• Study Section: Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
• Project Start: 1995-04-27
• Project End: 2002-03-31
• Budget Start: 1997-02-01
• Budget End: 1997-03-31
• Support Year: 2
• Fiscal Year: 1997

Institution

• Name: Emory University
• Department: Surgery
• Type: Schools of Medicine
• DUNS #: 042250712
• City: Atlanta
• State: GA
• Country: United States
• Zip Code: 30322

Publications

Kaplan, Steven A; Lee, Jeannette Y; O'Neill, Edward A et al. (2013) Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male 16:169-72

Kaplan, Steven A; Lee, Jeannette Y; Meehan, Alan G et al. (2011) Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol 185:1369-73

Kaplan, Steven A; Roehrborn, Claus G; McConnell, John D et al. (2008) Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol 180:1030-2;discussion 1032-3

Crawford, E David; Wilson, Shandra S; McConnell, John D et al. (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422-6; discussion 1426-7

Kaplan, Steven A; McConnell, John D; Roehrborn, Claus G et al. (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175:217-20; discussion 220-1